Balance how Tsumura's index exit affects your portfolio by scouting other potential candidates in the list of solid balance sheet and fundamentals (22 results) that could help stabilise benchmark-driven swings.
Tsumura’s story is still about a focused pharmaceutical business built around Kampo formulations, steady prescription demand in Japan and a growing foothold in China. The near term questions are more about execution than index status. You are essentially betting that management can keep converting this niche into consistent earnings, protect pricing in a regulated market and keep capital spending disciplined while margins hold up after a year of 17.9% earnings growth.
The FTSE All World exit mainly affects who owns the stock, not how many prescriptions get written next quarter. Index selling can bump up short term volatility, yet the key swing factors remain forecast earnings pressure, a dividend that is not well covered by free cash flow and relatively low current and projected returns on equity, all against a valuation that screens as good value compared to peers and fair value estimates.
Even so, there is a less comfortable angle to Tsumura that sits behind those attractive valuation and profit quality metrics...
There's only one way to know the right time to buy, sell or hold Tsumura. Head to Simply Wall St's company report for the latest analysis of Tsumura's Fair Value.
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
If Tsumura has put index mechanics and fundamentals back on your radar, it can be useful to widen the lens and line it up against other candidates that fit different roles in your portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com